Estrogenic prevention of luteinizing hormone releasing hormone agonist-induced bone loss.

ABSTRACT: Prostate cancer is a leading cause of death. As a hormone-driven cancer, prostate cancer is often treated with drugs (luteinizing hormone receptor agonists; LHRHa) or surgical approaches (orchidectomy; ORX) with the goal of reducing androgens. These approaches cause side effects such as bone loss. It is unclear if the side effects of these approaches are due to loss of androgens or loss of estrogens, as these approaches reduce both. We seek to evaluate if LHRHa and ORX have equivalent effects on bone, if the bone loss can be ameliorated by estrogen supplementation, and if estrogen supplementation alone is sufficient to improve bone mass while reducing androgen production. Herein, we evaluated bone microarchitecture, mechanical properties, and the cellular mechanism of LHRHa with subsequent

SUBMITTER: Wells KV 

PROVIDER: S-EPMC12777956 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature